Elicio Therapeutics (ELTX) Fundamental Analysis: Revenue, Earnings & Valuation

2.20 / 10

Underperform

Fundamentals rate Underperform, scoring 2.2/10. Positive points include a solid current‑liabilities ratio and strong interest‑coverage, but long‑term debt to working capital and PB‑ROE are weak. Overall, the company shows poor financial health, warranting a prudent stance.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight69.32%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.95%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-7.90%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value33.48

Score2/3

Weight2.68%

1M Return0.36%

PB-ROE

Value3.80

Score0/3

Weight23.35%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value1.44

Score1/3

Weight-4.66%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.03%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.39%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-7.59%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight31.50%

1M Return4.00%

Is ELTX fundamentally strong?

ELTX scores 2.20/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -4.95 P/E ratio, 119.75 P/B ratio, and 39.29% earnings growth, these metrics solidify its Underperform investment rating.